



RAPID DOSE THERAPEUTICS ANNOUNCES AGREEMENT WITH CHEMESIS INTERNATIONAL TO LICENSE QUICKSTRIP™ TECHNOLOGY IN PUERTO RICO

Toronto and Burlington, Canada, November 7, 2018 – ACME Resources Corp. (“ACME” or the “Company”) and **Rapid Dose Therapeutics Inc. (“RDT”)** are pleased to announce that RDT’s United States subsidiary, RDT Therapeutics Inc. (“RDT-US”), has signed an additional definitive five-year, renewable Managed Strip Services (MSS) Agreement with Chemosis International Inc. (CSE: CSI) (“Chemosis”) for the territory of Puerto Rico.

Under the Managed Strip Services Agreement, Chemosis has been granted a license to use RDT’s QuickStrip™ trademarks and proprietary delivery technology for cannabis products in Puerto Rico. Within the terms of the Agreement, RDT-US will provide licensing rights to Chemosis to produce, distribute and sell products across Puerto Rico using RDT’s QuickStrip™ delivery method for the cannabis market. RDT-US and Chemosis have established a prior definitive agreement to license QuickStrip™ in the state of California and will now continue to build and expand the QuickStrip™ global footprint into the Puerto Rican marketplace.

RDT’s game-changing, proprietary QuickStrip™ technology is a Quick, Convenient, Precise, Discreet™ oral fast-dissolving drug delivery system that offers an accurate dosing and smoke-free choice to consumers.

“RDT is excited to continue to develop its relationship with Chemosis to offer cannabis consumers in Puerto Rico a smoke-free delivery method that is consistent and precise.” explains Mark Upsdell, CEO of RDT. “With Chemosis’ worldwide reach, the QuickStrip™ brand will have the opportunity to establish and grow new markets around the globe.”

“Our partnership with RDT now allows us to bring an alternative cannabis delivery system to consumers in Puerto Rico,” said Edgar Montero, CEO of Chemosis. “This partnership allows us to bring the QuickStrip™ discrete and quick delivery system to the consumers of Puerto Rico. This partnership increases the reach of Quickstrip™ products with Chemosis and the company is a positive step forward in our business plan to provide consumers with high quality products.”

A Game-Changing Delivery System

About Rapid Dose Therapeutics

Rapid Dose Therapeutics, RDT, is a Canadian bio-technology company that provides innovative, proprietary drug delivery technologies designed to improve patient outcomes and quality of lives. Rapid Dose Therapeutics offers Quick, Convenient, Precise and Discreet™ choices to consumers and patients. RDT is

focused and committed to clinical research and product development for the healthcare manufacturing industry — including nutraceutical, pharmaceutical and cannabis industries. Within the cannabis sector, RDT provides a turn-key Managed Strip Service Program which enables RDT's QuickStrip™ proprietary drug delivery technology to be licensed by select partners. RDT is driven to expand globally into emerging markets, create value for both consumers and shareholders and continually create innovative solutions aimed at future market needs.

For more information, visit: www.rapid-dose.com

For media inquiries please contact:

info@rapid-dose.com

416-477-1052

1121 Walkers Line, Unit 3

Burlington ON Canada

L7N 2G4

About ACME - Proposed Business Combination

ACME and RDT have proposed a business combination which, when completed, will constitute a reverse take-over of ACME by the shareholders of RDT and the acquisition of RDT by ACME. The previously announced proposed amalgamation involving ACME, its wholly-owned subsidiary and RDT (the "Amalgamation") and all of the matters relating to the Amalgamation have been approved by more than 99% of the votes cast by ACME shareholders present in person or represented by proxy at an ACME shareholders meeting held on August 30, 2018 and by 100% of the votes cast by RDT shareholders present in person or represented by proxy at a RDT shareholders meeting held on August 27, 2018. For details of the proposed Amalgamation and other aspects of the proposed reverse take-over transaction, please refer to ACME's news release filed on ACME's profile on SEDAR at www.sedar.com on July 12, 2018 and the management information circular for the ACME shareholders meeting filed on ACME's profile on SEDAR at www.sedar.com on August 9, 2018.

More Information about ACME:

For more information about ACME, visit ACME's profile at www.sedar.com or contact Jorge Estepa, Corporate Secretary, 20 Adelaide Street East, Suite 200, Toronto, Ontario M5C 2T6 Tel: (416) 818-4035

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: *Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of products using the QuickStrip™ product delivery method, express, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of ACME and RDT as to future events or results and are believed to be reasonable based on information currently*

available to them. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement